CGRP ANTAGONISTS PRIOR AUTHORIZATION REQUEST

PRESCRIBER FAX FORM

ONLY the prescriber may complete and fax this form. This form is for prospective, concurrent, and retrospective reviews.

Incomplete forms will be returned for additional information. The following documentation is required for prior authorization consideration. For formulary information and to download additional forms, please visit https://www.bcbstx.com/provider/medicaid/pharmacy/rx-prior-auth

PATIENT AND INSURANCE	<u>EINFORMATION</u>	MATION			Today's Date:				
Patient Name (First):	Last:								
Patient Address:		City, State, Zip:		Patien	Patient Telephone:				
BCBSTX ID Number:		I	Group Number:	I					
PRESCRIBER/CLINIC INFO	RMATION								
Prescriber Name:					Contact Name:				
Clinic Name:			Clinic Address:						
City, State, Zip:			Phone #:	Secure Fax #:					
PLEASE ATTACH ANY AD	DITIONAL INFOR	MATION THAT SH	HOULD BE CONSIDE		THIS REQUEST				
Patient's Diagnosis-ICD coo	de plus descriptior	1:							
Medication Requested:			Stre	ength:					
Dosing Schedule:			Qua	antity per Mo	nth:				
For All Requests:									
		-			Yes 🗌 No				
-		-	tion started?						
2. Please list all agents th	e patient has pre	viously tried and	failed for treatment of	of this diagn	iosis (Please specify if the				
patient has tried brand-	-name products, g	eneric products, or	over-the-counter pro	ducts. Pleas	e specify start and end dates of				
drugs tried).									
	Da	ate(s):			Date(s):				
<u> </u>	Da	ite(s):			Date(s):				
	Da	ite(s):							
3. Please list all other me	dications the patie	ent will take in com	bination with the req	uested medi	cation for the treatment of this				
diagnosis.									
4. Please list all reasons t	for selecting the re	equested agent, st	rength, dosing sche	dule, and qu	uantity over alternatives (e.g.,				
contraindications, allere	gies, history of adv	verse drug reaction	is to alternatives, lowe	er dose has b	peen tried, information supporting				
dose over FDA max).									
5. Does the patient have	a diagnosis of sev	ere hepatic impairr	ment in the last 365 da	ays?	Yes 🗌 No				
6. Does the patient have									
8. Does the patient have									
per month and less tha	in 15 headache da	ys per month on a	verage in the last 90 o	days)?	Yes 🗌 No				
For Aimovig/Ajovy/Emgal			-	- /					
9. Does the patient have	•	c opioid therapy (q	reater than or equal to	o 60-days su	pply in the				
	-		-	-					
10. Does the patient have	a diagnosis of chro	onic migraines (def	fined as having greate	er than or equ	ual to 8 migraine				
days per month and gr	eater than or equa	I to 15 headache c	lays per month on ave	erage in the l	last 90 days)?□ Yes □ No				
• • •	1. Does the patient have a diagnosis of episodic cluster headaches (defined as having two cluster periods lasting								
	•		•	-	I to 3 months)?□ Yes □ No				
Please continue to the ne	xt page.								

Patient Name (First):	Last:		M:	DOB (mm/dd/yyyy):				
For Nurtec/Ubrelvy Requests:								
12. Does the patient have a diagnosis of migraine headache in the last 730 days?								
13. Has the patient tried and failed therapy with at least 2 different triptans?								
14. Does the patient have any FDA labeled contraindications to triptan therapy?								
If yes, please explain:								
15. Has the patient been on a strong CYP3A4 inhibitor or inducer in the last 30 days?								
Prescriber or Authorized Signature: Date:								
Please fax or mail this form to: Prime Therapeutics LLC, Clinical Review Departr 2900 Ames Crossing Road Eagan, Minnesota 55121	nent the inf me dis	CONFIDENTIALITY NOTICE: This communication is intended only for the use of the individual entity to which it is addressed and may contain information that is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please						
TOLL FREE Fax: 877.243.6930 Phone: 855.457.0	0407 no	notify the sender immediately by telephone at 866.202.3474 and return the original message to Prime Therapeutics via U.S. Mail. Thank you for your cooperation.						